Published in final edited form as:

J Chromatogr B Analyt Technol Biomed Life Sci. 2008 February 1; 862(1-2): 140–149. doi:10.1016/j.jchromb.2007.11.030.

Enantiospecific gas chromatographic-mass spectrometric analysis of urinary methylphenidate:

Implications for phenotyping

Natalie L. LeVasseur^{3,4}, Hao-Jie Zhu^{*,1}, John S. Markowitz^{1,2}, C. Lindsay DeVane², and Kennerly S. Patrick¹

¹Department of Pharmaceutical Sciences, Medical University of South Carolina, Charleston, SC

²Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC

³Department of Chemistry and Biochemistry, College of Charleston, Charleston, SC

Abstract

A chiral derivatization gas chromatographic-mass spectrometric (GC-MS) method for urine methylphenidate (MPH) analysis was developed and validated to investigate preliminary findings regarding a novel MPH poor metabolizer (PM). Detection was by electron impact (EI) ionization-selected ion monitoring of the N-trifluoroacetylpropylpiperidinium fragments from MPH and the piperidine-deuterated MPH internal standard. The PM eliminated ~ 70 times more *l*-MPH in urine (9 % of the dose over 0-10h), and ~ 5 times more of the *d*-isomer (10 % of the dose), than the mean values determined from 10 normal metabolizers of MPH. Only minor amounts of the metabolite *p*-hydroxy-MPH were found in the urine of both the PM and normal metabolizers, while the concentration of MPH lactam was not high enough to be detectable. The described method indirectly gauges the functional carboxylesterase-1 status of patients receiving MPH based on the evaluation of relative urine concentrations of *d*-MPH:*l*-MPH. Clinical implications concerning rational drug selection for an identified or suspected MPH PM are discussed.

Keywords

methylphenidate; esterase; pharmacogenetics; enantiomers; urine

1. Introduction

Attention-deficit/hyperactivity disorder (ADHD) is among the most common childhood neuropsychiatric conditions diagnosed and treated worldwide. Additionally, it is increasingly recognized as being prevalent among adults [1]. Psychostimulant medications typically represent first line agents in the pharmacotherapy of ADHD, foremost of these being *dl*-methylphenidate (MPH; Fig. 1). Optimization of pharmacotherapy in ADHD generally requires some empiricism and approximately 20-30% of ADHD patients do not respond

*Please send correspondence to: Hao-Jie Zhu . 173 Ashley Avenue, CRI, RM 405B, Charleston, SC 29425, Ph (843)-792-0372; Fax (843)-792-6318; zhuh@musc.edu

⁴Current address: Department of Pharmacology, Emory University, Atlanta, GA.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

favorably to *dl*-MPH at any dose [2]. New medications for ADHD continue to be developed and include enantiopure *d*-MPH [3].

Following oral administration of *dl*-MPH, stereoselective first-pass metabolism typically limits the systemic exposure of the *l*-isomer to only 1-3 % of the dose, while approximately 25% of *d*-MPH reaches the blood stream [4,5]. In effect, “in vivo resolution” of oral *dl*-MPH results in only the pharmacologically active *d*-isomer from appreciably accessing the central nervous system [6].

Most therapeutic drug monitoring studies of *dl*-MPH have utilized achiral analytical methods, and hence, incapable of investigating any potential correlations between pharmacodynamics and MPH enantiomeric disposition. However, Jonkman and coworkers [7] reported in a pilot study that plasma concentrations of both *l*-MPH and *d*-MPH were significantly higher in ADHD children who did not respond favorably ($n = 4$) to *dl*-MPH than in those who responded well ($n = 8$). Mean plasma *l*-MPH concentrations were found to be approximately 50% that of *d*-MPH, regardless of response status. It is noted that such relatively high *l*-MPH plasma concentrations are unusual except following transdermal administration [8].

Patrick and coworkers [9] applied chiral liquid chromatography-mass spectrometry (LC-MS) to a single dose pharmacokinetic study of twenty normal adult subjects orally dosed with immediate-release *dl*-MPH-HCl (0.3 mg/kg) with or without ethanol. In that study, one individual was found to have *l*-MPH plasma concentrations 1-2 orders of magnitude greater than typical *l*-MPH values, and *d*-MPH plasma concentrations were also well above expected values (Fig. 2). Further, this one individual, who we will refer to hereafter as a poor metabolizer (PM) of MPH, did not form any detectable ethylphenidate which is the esterase mediated transesterification product of concomitant MPH and alcohol. Whether this MPH PM status represents a distinct pharmacogenetic polymorphism, i.e., $\geq 1\%$ of the population, or only a rare metabolic defect, remains to be established. Pharmacogenomic studies are in progress [10].

The present investigation extends the plasma MPH isomeric disposition findings for this PM to urine analysis, which in turn was compared to urine MPH concentrations from 10 study peers (5 male; 5 female) previously found to exhibit normal MPH pharmacokinetics [9]. Urine sampling offers some advantages over plasma sampling for exploring MPH PM population prevalence: (a) MPH concentrates in urine, allowing more routine and less sensitive analytical instrumentation than chiral column LC-MS/MS [9]; (b) Urine sampling is less invasive and less expensive than plasma sampling; (c) Urine does not carry the risk of blood-borne disease transmission.

The following describes a practical gas chromatographic-mass spectrometric-electron impact (GC-MS-EI) method to establish normal versus PM MPH status based on relative urinary *l*-MPH versus *d*-MPH concentrations. GC separable MPH diastereomers were formed using commercial (*S*)-*N*-trifluoroacetylpropyl chloride (TFP-Cl) and piperidine-deuterated *dl*-MPH was utilized for analytical control. Earlier methods for enantiospecific urinary MPH analysis have used GC-nitrogen phosphorous detection [11] and GC-electron capture detection [12], and synthetic (*S*)-*N*-heptafluorobutyrylpropyl chloride with adamantanemethylamine as the internal standard.

As a secondary component to the present investigation, the prospect that the MPH PM may excrete elevated levels of normally minor MPH metabolites was explored. The metabolic fate of MPH in humans is well characterized. Rapid methyl ester hydrolysis usually limits the half-life to 2-3 hours [5], with the exception being the newly identified PM [9]. This deesterification pathway yields the inactive [13] metabolite ritalinic acid (Fig. 1), which accounts for most of a MPH dose in the urine [14,15]. The highly elevated plasma *l*-MPH concentrations observed

in the MPH PM presented the possibility that compensatory increases in usually minor metabolic pathways might prevail given the apparent impairment in the enzymatic hydrolysis rate. Accordingly, the pathways of para-hydroxylation to the active metabolite HO-MPH [13] and/or 6'-oxidation [14] to the inactive [15] MPH lactam were also examined. Evidence of enantioselective hydroxylation of *l*-MPH in rats [16] and baboons [6], as well as the possible accumulation of *l*-HO-MPH in brain [6], further compelled the investigation of alternative oxidative biotransformation pathways.

2. Experimental

dl-MPH·HCl in methanol (1 mg/mL calculated as free base; Cerilliant, Round Rock, TX), TFP-Cl in dichloromethane (1M; Aldrich, St. Louis, MO), sodium carbonate (Fischer Scientific, Fair Lawn, NJ), acetonitrile (Mallinckrodt Inc, Paris, KT), *n*-butyl chloride (Burdick & Jackson, Muskegon, MI), and gluculase (glucuronidase / arylsulfatase; Roche Applied Sciences, Indianapolis, IN) were used. *dl*-HO-MPH·HCL [13,17,18] and piperidine deuterated *dl*-MPH·HCL [9,17-19] were synthesized in house and contained approximately 25% of the D₅-isotopolog and no detectable D₀. It is noted that piperidine deuterated D₉-MPH·HCl has recently become commercially available (Cerilliant). The MPH lactam was donated by Ciba-Geigy Corp.

2.1. Research Subjects

The study was conducted in the General Clinical Research Center at the Medical University of South Carolina. The Office of Research Integrity approved the written informed consent provided by each subject. Normal adult volunteers were used, aged 23-40 years and deemed healthy based on medical history, physical examination, 12-lead electrocardiogram, and routine laboratory tests including complete blood count, serum electrolytes, blood glucose, urinalysis, urine drug screen and liver function indices. All subjects were also non-smokers within 15% of ideal body weight.

2.2. Drug Administration and Sampling

The study required subjects to arrive the evening prior to the test session, begin fasting, and stay overnight. Subjects were given fifteen min to eat an entire standard breakfast and then received an oral dose of immediate-release *dl*-MPH·HCl (Ritalin®; 0.3 mg/kg) 1 h later using 5 and 10 mg tablets with the 5 mg tablets cut to the nearest 2.5 mg. A standardized lunch was also provided during the course of the study and consumed within 30 min. All urine was collected over 10 h from the time of MPH dosing, total volumes were recorded, and samples stored at 2-5°C throughout the day to minimize any potential post-sampling hydrolysis [20]. Three 10 mL aliquots from the total collected urine were taken and frozen at -70°C until analysis. Blank urine for the calibrators was collected from a volunteer not exposed to *dl*-MPH·HCl.

2.3. Instrumentation

All analyses were conducted with an Agilent Model 6890 GC-5973N MS with ChemStation. GC separations were on a 30 m × 0.32 mm, 0.25 µm film thickness (DB-5 J & W Scientific, Folsom, CA) 5% phenylmethylpolysiloxane fused-silica column. Pulsed-splitless injections (2 µL) were used. The injector port was operated at 250 °C and the helium carrier gas linear velocity was 50 cm/s. EI ionization (70 eV) was used for MPH and the MPH lactam analyses. Negative ion chemical ionization (NICI; methane) was used to maximize sensitivity in HO-MPH analyses.

2.4. Method Validation and MPH Sample Analysis

The lower limit of quantification (LLOQ) was estimated when the accuracy was within 80-120%, and the relative standard deviation (%R.S.D.) of precision studies was within 20%. The accuracy and precision of the assay were determined from the analysis of blank human urine samples spiked with MPH isomers at three different concentrations (20; 150; 500 ng/mL) on three successive days. The extraction recovery of MPH (40; 300; 1,000 ng/mL) and piperidine deuterated *dl*-MPH (1000 ng/mL) was performed by comparing the peak areas of extracted samples to that of extracted blank urine spiked after work-up with MPH and piperidine deuterated *dl*-MPH that present 100% recovery. Five determinations of each concentration have been applied to all these validation studies [21].

For human sample analysis, blank urine aliquots (2 mL) in 15 mL screw-cap test tubes were fortified with *dl*-MPH to provide 0; 100; 250; 1,000; 5,000 and 10,000 ng/mL of each MPH isomer, generating 2 separate enantiomeric calibration curves. Subject urines were thawed and 2 mL aliquots were run in parallel with the calibrators. Piperidine deuterated *dl*-MPH (10 µg) was added as an internal standard to the calibrators and unknowns. The pH was adjusted to approximately 9.5 using 1.2 M sodium carbonate and extracted with 3 mL of *n*-butyl chloride : acetonitrile (4:1) by vortexing for one min. The organic phases were transferred into 4 mL screw-cap silanized vials and the solvent was evaporated to dryness under nitrogen. Chiral derivatization used TFP-Cl (200 µL: 1 M in dichloromethane chloride) with Teflon® capped vials heated at 58 °C for 35 min. The samples were diluted with dichloromethane to a total volume of 0.5 mL and transferred to silanized GC autosampler vials for GC-MS analysis. MPH isomers were detected by EI selected ion monitoring (SIM) of the TFP-piperidyl fragment *m/z* 277 for the analyte and *m/z* 282 for the pentadeuterated isotopolog. The GC was held at 70 °C for 1.5 min, then ramped to 315 °C at 15 °C/min and held for 4 min leading to a total run time of 18 min.

2.5. HO-MPH and *dl*-MPH lactam reference standards

The standard of *dl*-HO-MPH (1 µg) was treated with TFP-Cl (200 µL; 1 M in dichloromethane) at 58 °C for 35 min to yield N,O-(TFP)₂ diastereomeric derivatives of *d*- and *l*-HO-MPH suitable for chiral analysis. NICI (methane) was used for urine analysis, with detection by SIM of the base peak ion *m/z* 441 [M-TFP; *m/z* 635 M (10%)]. The GC was held at 120 °C for 1.5 min, then ramped to 280 °C at 15 °C/min and held for 6 min. It was then ramped at 20 °C/min to 315 °C and held for 11 min for a total run time of 31 min. The *dl*-MPH-lactam, being incapable of chiral derivatization, was used directly as a methanolic solution (~50 µg in 150 µL) for GC-MS-EI. The GC was held at 70 °C for 1.5 min, then ramped at 20 °C/min to 315 °C and held for 16 min: total run time 30 min.

2.6. Screening for HO-MPH and MPH lactam in urine

Urine (2 mL) was added to screw cap test tubes (15 mL) and the pH adjusted to ~5.5 with 2 M sodium acetate. Glusulase (50 µL β-glucuronidase/arylsulfatase) was added and then incubated for 2.5 h at 37 °C. The pH was adjusted to ~ 9.5 with 1.2 M sodium carbonate and the samples were extracted with *n*-butyl chloride : acetonitrile (3 mL; 4:1) by vortexing for one min. The organic phases were transferred to 4 mL screw-cap silanized vials and the solvent was evaporated to dryness under nitrogen. The residues were treated with TFP-Cl (200 µL: 1 M in dichloromethane) as above. The cooled solutions were transferred into GC autosampler vials and brought to 0.5 mL with dichloromethane for analysis. The MPH lactam was not detectable by GC-MS-EI-total ion monitoring of an extracted urine sample from the MPH PM, nor from that of a normal MPH metabolizer. Further, extracted base peak 6'-oxopiperidinium ion profiling was used to enhance the potential for detection.

3. Results

3.1. Method validation

An enantiospecific GC-MS-EI method for analyzing MPH was developed, validated (Table 1) and used to distinguish the unique MPH urinary excretion profile of a MPH PM relative to normal individuals (Table 2; Fig.3). Detection was by SIM of the high abundance (74%) m/z 277 TFP-piperidine fragment of MPH [piperidinium m/z 84 (100%)]. Chiral derivatization and a GC temperature program allowed baseline separation of *d*-TFP-MPH (t_R = 13.2 min) and *l*-TFP-MPH (t_R = 13.5 min). The isomer elution order was established as previously described [22,23]. Piperidine-deuterated MPH provided for analytical control in quantitative determinations (Fig. 4). This internal standard was composed of all deuterium isotopologs from D₂ - D₈, with D₅ in the highest percentage, i.e., approximately 25% [17,18]. Accordingly, the D₅-TFP-MPH fragment m/z 282 was monitored. Urine calibrators fortified with racemic MPH generated calibration plots for 0 - 1,000 ng/mL *d*-MPH (R^2 = 0.998) and *l*-MPH (R^2 = 0.998). These calibrators were run in parallel with the unknowns to permit quantitation by linear regression. Urine calibrators at 5,000 ng/mL and 10,000 ng/mL were also analyzed with the calibrators in the event that such high MPH concentrations may be relevant to the poor metabolizer. However, with these 2 highest concentrations being several-fold higher than found in the urine of any subject in the present 0.3 mg/kg *dl*-MPH oral dose study, these two highest concentration calibrators were not entered into the linear regression analysis to avoid biasing the low ng/mL *l*-MPH determinations found for the normal metabolizer urine.

LLOQ was found to be 10 ng/mL when using 2 μ L injections from 500 μ L reconstituted 2 mL urine extracts. The accuracy and precision were determined at three concentrations (20, 150, 500 ng/mL) in five replicates. The results in Table 1 showed the accuracy and precision of the developed method meet generally accepted requirements [21]. The recovery of MPH at the concentrations of 40, 300, 1000 ng/mL and piperidine deuterated *dl*-MPH (1000 ng/mL) were found to be 62.71 % $\pm$ 9.30, 63.75 % $\pm$ 3.30, 70.01 % $\pm$ 9.95, and 64.55 % $\pm$ 6.50, respectively.

3.2. Differential excretion of *d*- and *l*-MPH in a PM

The PM was found to have excreted nearly 70 times more *l*-MPH, and 5 times more *d*-MPH, than the mean values for 10 normal metabolizers of *dl*-MPH (Table 2). The isomeric MPH concentrations quantified from the PM in duplicate sample analyses were 958 and 1,059 ng/mL for *l*-MPH with 1,176 and 1,194 ng/mL for *d*-MPH. All subjects in the present study had previously been phenotyped through plasma analyses [9].

3.3. Potential alternate metabolic pathways

Reference standards of *dl*-HO-MPH-HCl (Fig. 5) and the MPH lactam (Fig. 6) were analyzed by GC-MS to explore the possibility of alternative metabolic pathways being favored in an individual with impaired esterase activity. The GC-MS of reference standard *dl*-HO-MPH demonstrated baseline resolution of the two isomers following chiral derivatization. Tentative assignment of the *d*-(*R,R*) and *l*-(*S,S*)-HO-MPH configurations to the (TFP)₂-HO-MPH isomers generating chromatographic peaks at t_R = 20.9 min and 22.2 min, respectively, was based on the corresponding elution orders of enantiomeric TFP-MPH [22] and TFP-ethylphenidate [23].

Following glucuronide cleavage with glucuronidase, and chiral derivatization, GC-MS analysis of urine from the MPH PM and from a normal metabolizer revealed chromatographic peaks corresponding to the HO-MPH isomers. However, neither sample appeared to contain more than low ng/mL concentrations of HO-MPH, albeit more readily detectable for the PM. This qualitative assessment did not include an internal standard and was not explored further owing to the largely negative finding.

The MPH lactam reference standard eluted at $t_R = 11.5$ min (Fig. 6) but was not detectable in either the PM nor normal MPH metabolizer urine samples.

4. Discussion

A MPH PM was recently identified by the unprecedented high plasma concentrations of *l*-MPH and by the absence of plasma *d*- or *l*-ethylphenidate when *dl*-MPH was dosed with ethanol. *d*-MPH concentrations were also considerably higher than normal values [9]. Based on the present study, the especially high concentration of *l*-MPH detected in the plasma of the PM (Fig.2) generalizes to the urine *l*-MPH concentration when compared to that from 10 normal subjects. Accordingly, the enantiospecific GC-MS method developed here can serve as an expedient to phenotyping MPH metabolism status. Broader population based studies will be necessary to establish whether this MPH PM represents a rare genetic defect or is the first evidence of a distinct polymorph (i.e., being found in a population frequency of at least 1 %).

Chiral derivatization GC methods for enantiospecific urinary MPH analysis have been reported using nitrogen phosphorous detection [11] or electron capture detection [12] and in-house synthesized N-heptafluorobutylpropyl chloride. The present method benefits from the molecular specificity of MS detection and utilizes commercially available N-trifluoropropyl chloride to form GC separable MPH derivatives. Achiral GC methods for urinary MPH analyses have also been reported [24-26] and the total MPH isomer concentrations reported in such earlier studies (Table 3) are generally consistent with those reported here for normal metabolizers.

Carboxylesterase-1 (CES1A1) rapidly hydrolyzes *dl*-MPH and results in a large distortion of plasma MPH isomers concentration, with *d*-MPH $\gg$ *l*-MPH [9]. In most individuals, this metabolic pathway accounts for the short MPH elimination half-life of 2-3 h [5]. Consequently, multiple daily dosing is generally required when using immediate-release MPH to ameliorate the symptoms ADHD throughout the day [5]. Alternatively, a single dose of modified -release MPH is required [27]. Most MPH formulations used at the present time are racemic mixtures of *d*- and *l*-MPH (Fig.1; R = CH₃). However, enantiopure *d*-MPH formulations have recently become available [3]. *d*-MPH is generally regarded as the active isomer in the treatment of ADHD, while *l*-MPH has no demonstrable therapeutic effects [28]. Nevertheless, several lines of experimental evidence support at least some pharmacological activity being attributable to *l*-MPH [5]. This activity now includes the enantioselective interaction of *l*-MPH with ethanol to yield the transesterification product ethylphenidate (Fig. 1, R = CH₂CH₃). This drug interaction is accompanied by a significant elevation in plasma *d*-MPH [9].

In the MPH PM, plasma *l*-MPH actually exceeded that of *d*-MPH. Further, the maximum plasma concentration (C_{max}) of *d*-MPH in the PM was approximately twice that of the normal subject mean values. Further, only in the PM was no ethylphenidate detectable when administered concomitant ethanol-MPH [9]. Taken together, these metabolic anomalies of the PM are consistent with a *CES1A1* [29] null or reduced activity allele. This hypothesis has recently been supported by preliminary genotyping studies [10]. In that this esterase also prominently clears cocaine from the systemic circulation, it may be speculated that such PM (s) are pharmacogenetically predisposed to idiosyncratic cocaine responses, including overdose.

Low esterase activity has had clinical implications for response to other ester containing drugs such as succinylcholine. In this latter precedent, a bimodal distribution of cholinesterase activities was found in humans [30].

The majority of an oral dose of *dl*-MPH can be accounted for in the urine as the deesterified form of MPH, ritalinic acid (Fig. 1). Relatively low concentrations of MPH have been reported

in urinary elimination studies (Table 3), however, these concentrations still greatly exceed those of plasma [5]. Thus, urine MPH analysis avoids most analytical sensitivity issues. The minor MPH metabolites HO-MPH and MPH lactam have been reported to be primarily, if not exclusively, eliminated in the urine as their corresponding carboxylic acids [14,15]. The alkalized urine liquid-liquid extraction protocol used in the present study prevented recovery of such zwitterionic and / or acidic biotransformation products. Accordingly, the absence of appreciable HO-MPH and MPH lactam in the test urine samples does not, in and of itself, preclude the possibility of such oxidative biotransformations from occurring. These pathways might compensate for the impaired esterase function of the MPH PM. While intact esters of HO-MPH and MPH lactam do not appear to be pertinent to MPH urinary mass balance, even in the PM, the present report offers characterization of the GC-MS properties of the metabolites HO-MPH (Fig. 5) and MPH lactam (Fig. 6) to serve as reference analytical chemistry in the ongoing exploration of MPH metabolism.

Piperidine deuterated MPH was chosen as the internal standard rather than methyl-deuterated MPH [27,31]. This standard allowed acquisition of the EI generated high abundance TFP-piperidyl fragment which favors higher sensitivity (higher relative abundance fragment ion) when compared to any methyl deuterated MPH EI ions. Furthermore, use of this internal standard avoided any potential deuterium isotope effect differentially influencing hydrolytic loss during sample work-up. Additionally, methyl-deuterated *dl*-MPH was found to generate artifactual unlabeled MPH in an LC system containing methanol (unpublished observation).

Use of stable isotope analogues for analytical control in drug analysis from biological samples can optimize not only accuracy and precision, but also may enhance sensitivity through the carrier effect [32]. Deuterated MPH avoids the common, but problematic use of ethylphenidate (Fig.1) as an internal standard in MPH analysis. Ethylphenidate has previously been identified as a metabolite in humans receiving a single dose of *dl*-MPH and ethanol [9,33], and this metabolite is readily detectable in urine of such subjects [34]. In the context of MPH - ethanol co-abuse, detection of urinary ethylphenidate could serve as a forensic biomarker in a fashion analogous to urinary anhydroecgonine ethyl ester detection indicating co-abuse of ethanol and smoked cocaine [35].

The present GC-MS-EI method provides a routine, rapid and non-invasive approach to phenotyping MPH metabolizer status with the potential for improving rational ADHD drug selection for individuals with compromised esterase-mediated MPH clearance. The special significance of these results are not so much the establishment of absolute urinary concentrations of *d*- and *l*-MPH, but rather the ability to identify a MPH PM by the *relative* amounts of *d*-MPH versus *l*-MPH in urine. A very pronounced qualitative difference in the urinary MPH chromatogram for the PM is readily apparent upon comparison to that of a representative normal metabolizer (Fig. 3). The PM excreted almost equal amounts of *d*- and *l*-MPH, while all 10 normal metabolizers excreted only a small fraction of *l*-MPH relative to *d*-MPH. Accordingly, a preliminary guideline for phenotyping via the present method is proposed: When the urinary ratio of *d*-MPH to *l*-MPH approaches unity, the subject becomes a candidate for PM status; when the ratio of *d*-MPH to *l*-MPH is approximately ≥ 10 , the subject likely exhibits wild-type esterase function.

Acknowledging the limitations of evaluating urine from only 11 total subjects in the present study, it is noted that there was no indication of any intermediate or ultrarapid metabolic phenotypes in this small population. There were clear differences between subjects known to be normal metabolizers ($n=10$) and the subject ($n=1$) that had previously been identified as a PM.

The apparent bimodal distribution of esterase activity in this preliminary investigation contrasts with that of some other Phase I drug metabolizing enzymes systems such as the unimodal distribution of CYP3A4 or tetramodal distribution of CYP2D6. Nevertheless, such guidelines for delineation of normal versus PMs of MPH would be expected to be further refined as urinary values from a much larger population are determined.

In the pilot therapeutic drug monitoring study by Jonkman and associates [7], children with ADHD who displayed elevated *l*- and *d*-MPH plasma concentrations exhibited significantly less efficacy. However, little if any such plasma *l*-MPH - efficacy inverse correlations have been reported for transdermal *dl*-MPH. *l*-MPH reaches at least 10 times greater plasma concentrations by the transdermal route than by the oral route, but still only attains 40-60% of the plasma concentration of *d*-MPH [8]. If a correlation between therapeutic effects and MPH PM status is found to exist, alternative pharmacotherapies such as atomoxetine or amphetamine may be appropriate in this subset of esterase compromised patients.

Acknowledgments

The authors gratefully appreciate the important contributions of the Medical University of South Carolina's General Clinical Research Center in conducting these human subject studies and the MUSC University Research Committee for instrumentation support. This work was supported through NIH RO1DA-15797, RO1AA016707 and GCRC NIH MO1 RR01070.

References

- [1]. Biederman J, Spencer T. J Atten Disord 2002;6(Suppl 1):S101. [PubMed: 12685524]
- [2]. Markowitz JS, Straughn AB, Patrick KS. Pharmacotherapy 2003;23:1281. [PubMed: 14594346]
- [3]. Patrick KS. Drugs 2006;66:669.
- [4]. Modi NB, Wang B, Noveck RJ, Gupta SK. J Clin Pharmacol 2000;40:1141. [PubMed: 11028253]
- [5]. Patrick KS, Gonzalez MA, Straughn AB, Markowitz JS. Expert Opin Drug Deliv 2005;2:121. [PubMed: 16296740]
- [6]. Ding YS, Gatley SJ, Thanos PK, Shea C, Garza V, Xu Y, Carter P, King P, Warner D, Taintor NB, Park DJ, Pyatt B, Fowler JS, Volkow ND. Synapse 2004;53:168. [PubMed: 15236349]
- [7]. Jonkman LM, Verbaten MN, de Boer D, Maes RA, Buitelaar JK, Kemner C, van Engeland H, Koelega HS. Psychiatry Res 1998;78:115. [PubMed: 9579707]
- [8]. Heal DJ, Pierce DM. CNS Drugs 2007;20:713. [PubMed: 16953648]
- [9]. Patrick KS, Straughn AB, Minhinnett RR, Yeatts SD, Herrin AE, DeVane CL, Malcolm R, Janis GC, Markowitz JS. Clin Pharmacol Ther 2007;81:346. [PubMed: 17339864]
- [10]. Markowitz, J.; Wang, J-S.; DeVane, C.; Yuan, H-J.; Zhu, H-J.; Malcolm, R.; Donovan, J.; Johnson, J.; Patrick, K. 47th Annual Meeting; NCDEU, Boca Raton, FL. 2007;
- [11]. Lim HK, Hubbard JW, Midha KK. J Chromatogr 1986;378:109. [PubMed: 3733964]
- [12]. Srinivas NR, Hubbard JW, Korchinski ED, Midha KK. J Pharm Sci 1992;81:747. [PubMed: 1403717]
- [13]. Patrick KS, Kilts CD, Breese GR. J Med Chem 1981;24:1237. [PubMed: 7328584]
- [14]. Bartlett M, Egger H. Fed Proc 1972;31:537.
- [15]. Faraj BA, Israili ZH, Perel JM, Jenkins ML, Holtzman SG, Cucinell SA, Dayton PG. J Pharmacol Exp Ther 1974;191:535. [PubMed: 4473537]
- [16]. Patrick K, Caldwell R, Davis K, Mueller R, Breese G. Fed Proc 1986;46:933.
- [17]. Patrick K, Kilts C, Breese G. J Labelled Compound Radiopharm 1981;9:485.
- [18]. Patrick KS, Ellington KR, Breese GR, Kilts CD. J Chromatogr 1985;343:329. [PubMed: 4066874]
- [19]. Patrick KS, Jarvi EJ. J. Chromatogr. Biomed. Appl 1990;528:214-220.
- [20]. Portoghese P, Malspeis L. Pharm Sci 1961;50:494.

- [21]. Shah VP, Midha KK, Findlay JWA, Hill HM, Hules JD, McGilveray IJ, McKay G, Miller KJ, Patnaik RN, Powell ML, Tonelli A, Viswanathan CT, Yacobi A. *Pharmaceut Res* 2000;17:1551–1557.
- [22]. Patrick KS, Caldwell RW, Ferris RM, Breese GR. *J Pharmacol Exp Ther* 1987;241:152. [PubMed: 3572779]
- [23]. Patrick KS, Williard RL, VanWert AL, Dowd JJ, Oatis JE Jr. Middaugh LD. *J Med Chem* 2005;48:2876. [PubMed: 15828826]
- [24]. Milberg RM, Rinehart KL Jr. Sprague RL, Sleator EK. *Biomed Mass Spectrom* 1975;2:2. [PubMed: 1131389]
- [25]. Schubert B. *Acta Chem Scand* 1970;24:433. [PubMed: 5426217]
- [26]. Wells R, Hammond KB, Rodgerson DO. *Clin Chem* 1974;20:440. [PubMed: 4818196]
- [27]. Markowitz JS, Straughn AB, Patrick KS, DeVane CL, Pestreich L, Lee J, Wang Y, Muniz R. *Clin Pharmacokinet* 2003;42:393. [PubMed: 12648029]
- [28]. Srinivas NR, Hubbard JW, Quinn D, Midha KK. *Clin Pharmacol Ther* 1992;52:561. [PubMed: 1424430]
- [29]. Sun Z, Murry DJ, Sanghani SP, Davis WI, Kedishvili NY, Zou Q, Hurley TD, Bosron WF. *J Pharmacol Exp Ther* 2004;310:469. [PubMed: 15082749]
- [30]. Jensen FS, Skovgaard LT, Viby-Mogensen J. *Acta Anaesthesiol Scand* 1995;39:157. [PubMed: 7793180]
- [31]. Zhu HJ, Wang JS, DeVane CL, Williard RL, Donovan JL, Middaugh LD, Gibson BB, Patrick KS, Markowitz JS. *Drug Metab Dispos* 2006;34:1116. [PubMed: 16621932]
- [32]. Garland WA, Barbalas MP. *J Clin Pharmacol* 1986;26:412. [PubMed: 2942579]
- [33]. Markowitz JS, DeVane CL, Boulton DW, Nahas Z, Risch SC, Diamond F, Patrick KS. *Drug Metab Dispos* 2000;28:620. [PubMed: 10820132]
- [34]. Thomson M, Dowd J, Markowitz J, DeVane C, Patrick K. *J Clin Pharmacol* 2002;42:1069. Abstr
- [35]. Myers AL, Williams HE, Kraner JC, Callery PS. *J Forensic Sci* 2005;50:1481. [PubMed: 16382849]

Fig. 1. Structures of MPH enantiomers and corresponding human metabolites . Figure adapted from Patrick et al. [16].

Fig. 2.
l-MPH plasma concentration over time for the poor MPH metabolizer (●) compared to the mean values for 19 normal metabolizers (○). Subjects received MPH-HCl (0.3 mg/kg).

Fig. 3.

GC-MS-electron impact ionization of urine extracts from a MPH normal metabolizer (left) and from the MPH PM (right). Detection was by selected ion monitoring of the TFP-piperidinium fragment m/z 277. Chiral derivatization generated separable diastereomers and the piperidine-deuterated MPH provided analytical control (D₅-chromatograms). The urinary concentration of both *l*-MPH and *d*-MPH was greatly elevated in the PM.

Fig. 4. GC-MS-EI total ion monitoring of a D₂-D₈ deuterated MPH isotopolog mixture. Selected monitoring of D₅-MPH (TFP-piperidinium fragment *m/z* 282) served as the internal standard.

Fig. 5. GC-MS-NICI ion chromatogram of reference standard N,O-bis-TFP-*dl*-HO-MPH. The assignment of *d*-(*R*:*R'*)-HO-MPH ($t_R = 20.88$ min) and *l*-(*S*:*S'*)-HO-MPH ($t_R = 22.18$ min) configurations were tentatively assigned-see Results. p-Hydroxylation is a minor MPH metabolic pathway in humans but was investigated as an alternative metabolic pathway for the MPH esterase PM.

Fig. 6. GC-MS-EI total ion monitoring of the MPH lactam metabolite reference standard. This metabolite was not detectable in urine. This 6'-position oxidative metabolite is a minor metabolic pathway in humans but was investigated as an alternative metabolic pathway for the MPH esterase PM.

Table 1
Intra- and inter-day precision and accuracy of GC-MS analysis of MPH enantiomers in human urine

	Spiked concentration (ng/mL)					
	20		150		500	
	d-MPH	l-MPH	d-MPH	l-MPH	d-MPH	l-MPH
Batch 1 (n=5)						
Observed intra-day mean (ng/mL)	19.28 ± 0.79	19.66 ± 0.61	143.04 ± 5.59	145.89 ± 6.83	499.25 ± 7.15	526.61 ± 26.23
Intra-day precision (%)	4.07	3.12	3.91	4.68	1.43	4.98
Intra-day accuracy (%)	96.40	98.31	95.36	97.26	99.85	105.32
Batch 2 (n=5)						
Observed intra-day mean (ng/mL)	18.78 ± 0.68	20.04 ± 2.15	149.31 ± 3.48	146.38 ± 8.25	520.80 ± 16.64	517.80 ± 34.03
Intra-day precision (%)	3.64	10.70	2.33	5.64	3.20	6.57
Intra-day accuracy (%)	93.89	100.21	99.54	97.59	104.16	103.56
Batch 3 (n=5)						
Observed intra-day mean (ng/mL)	20.74 ± 0.98	20.98 ± 1.76	143.03 ± 1.99	136.79 ± 11.30	520.15 ± 43.52	500.70 ± 36.49
Intra-day precision (%)	4.74	8.40	1.39	8.26	8.37	7.29
Intra-day accuracy (%)	103.71	104.89	95.35	91.19	104.03	100.14
Inter-day (n=15)						
Observed inter-day mean (ng/mL)	19.60 ± 1.15	20.23 ± 1.62	145.13 ± 4.78	143.02 ± 9.49	513.40 ± 27.24	515.04 ± 32.12
Inter-day precision (%)	5.88	8.03	3.30	6.64	5.31	6.24
Inter-day accuracy (%)	98.00	101.14	96.75	95.35	102.68	103.01

Table 2
MPH excreted in 10 h urine following a 0.3 mg/kg oral dose of *dl*-MPH·HCl^{a,b}

	<i>dl</i> -MPH Dose (0.3 mg/kg)	Total Urine Volume (mL)	Urinary <i>d</i> -MPH conc (ng/mL)	Urinary <i>l</i> -MPH conc (ng/mL)	Average <i>d</i> -MPH conc (ng/mL)	Average <i>l</i> -MPH conc (ng/mL)	^a % <i>d</i> -MPH Dose Excreted Unchanged	^a % <i>l</i> -MPH Dose Excreted Unchanged	% Total Dose Excreted Unchanged
Poor Metabolizer									
1	22.5	2550	1,176	1,059	1,184 ± 11	1,009 ± 71	10.5	9.0	9.7
duplicate			1,192	958					
Normal Males									
1	27.5	2185	418	ND	325 ± 133	25 ± 12	3.0	ND	1.5
2	27.5	1720	278	18.2			2.0	0.1	1.1
3	20.0	2840	392	43.1			3.9	0.4	2.2
4	25.0	2155	425	24.2			3.4	0.2	1.8
5	32.5	2230	110	15.8			0.7	0.1	0.4
Normal Females									
1	17.5	1790	146	18.3	176 ± 42	20 ± 2	1.7	0.2	0.9
2	22.5	1560	154	ND			1.4	ND	0.7
3	22.5	2770	225	ND			2.0	ND	1.0
4	22.5	2550	218	21.4			1.9	0.2	1.1
5	20.0	2450	138	ND			1.4	ND	0.7

ND- not detected; MPH concentrations calculated as free base.

^a based on a half of the dose (50:50 mixture of *d,l*-MPH)

^b Average of duplicate determinations

Table 3

Literature urinary MPH values in humans

Reference	Method	Dose	MPH reported	Comments
11	GC-NPD	20 mg	<i>d</i> -MPH: ~400 ug <i>l</i> -MPH: ~5 ug	Chiral derivatization; 11 h cumulative; adult
12	GC-ECD	40 mg	<i>d</i> -MPH: 53 ug <i>l</i> -MPH: 5 ug	Chiral derivatization; 16 h cumulative; adult
24	GC-MS	0.4 mg/kg	1.17 ug/mL	Achiral; 3 h; adult
18	GC-MS	0.3 mg/kg	0.051-0.274 ug/mL	Achiral; 24 h; adult
25	GC-FID	unknown	0.8-40 ug/mL	Achiral; forensic
26	GC-FID	10 mg	1.58 ug/mL	Achiral; 6 h; children

GC- gas chromatography; NPD- nitrogen phosphorous detection; ECD- electron capture detection; MS- mass spectrometry; FID- flame ionization detection.